<DOC>
	<DOCNO>NCT01870895</DOCNO>
	<brief_summary>To demonstrate superiority YM060 placebo global assessment relief overall IBS symptom stool form normalization , evaluate safety female patient diarrhea-predominant irritable bowel syndrome ( D-IBS ) .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety YM060 Female Patients With Diarrhea-predominant Irritable Bowel Syndrome ( IBS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Ramosetron</mesh_term>
	<criteria>1 . Patients satisfy Rome III Diagnostic Criteria 2 . Patients whose â‰¥25 % stool loose watery &lt; 25 % hard lumpy stool 3 . Patients abdominal pain discomfort 4 . Patients occurrence IBS symptom follow test conduct organic change observe Pancolonoscopy contrast enema 1 . Patients history surgical resection stomach , gallbladder , small intestine large intestine 2 . Patients history current evidence inflammatory bowel disease 3 . Patients history current evidence colitis ischemic 4 . Patients concurrent infectious enteritis 5 . Patients concurrent hyperthyroidism hypothyroidism 6 . Patients concurrent active peptic ulcer 7 . Patients concurrent disease may affect digestive tract passage large intestinal function likely interfere proper assessment IBS abdominal pain/discomfort</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>YM060</keyword>
	<keyword>Ramosetron</keyword>
	<keyword>Diarrhea-predominant Irritable Bowel Syndrome</keyword>
</DOC>